O&G SAQs · Antenatal care — maternal medicine
Preeclampsia prediction and prevention — structured SAQ (15 marks)
FRANZCOG-format structured SAQ on preeclampsia prediction and prevention: risk-factor assessment by the NICE and USPSTF checklist, the full aspirin and calcium prescription with ASPRE and Roberge evidence, the Fetal Medicine Foundation competing-risks model with SPREE performance data, and honest counselling about residual risk. Per-sub-part marking rubric included.
On this page
Study tools
Target exams
How this SAQ is marked
Twelve SAQs, 180 marks, two two-hour papers — about 15 marks and 20 minutes each. This question rewards a prescription, not a discussion: name the model, name the drug, name the dose, name the gestations, name the trial. [3][1]
Reveal model answer and mark schemeShowHide
(a) Risk assessment (4 marks)
One mark for naming the model, two for correctly identifying her factors, one for the decision. [3][8]
- Model used: the risk-factor checklist adopted by NICE, the USPSTF and ANZ practice — one high-risk factor, or two moderate-risk factors, triggers aspirin.[3][8]
- High-risk factors present: previous hypertensive disease in pregnancy (preeclampsia at 31 weeks). That alone is sufficient.[3]
- Moderate-risk factors present: age 40 years or more is not yet met at 39, but booking body mass index of 35 kg/m2 or more is present. Multiparity means nulliparity does not apply.[3]
- Decision: she qualifies on a single high-risk factor, so she starts aspirin today. Her early-onset index disease also puts her at the higher end of recurrence risk — the pooled recurrence of preeclampsia is around one in five and rises the earlier and more severe the index episode.[9][3]
(b) The preventive prescription (5 marks)
One mark each for: drug and dose; start gestation; stop gestation; calcium with its indication; the trial evidence. [1][2][7]
| Element | Prescription |
|---|---|
| Drug and dose | Low-dose aspirin; ASPRE used 150 mg nightly. ANZ practice commonly 100 to 150 mg daily; NICE 75 to 150 mg; USPSTF 81 mg daily |
| Timing of the dose | At night, as in ASPRE and FIGO guidance |
| Start | Ideally 11 to 14 weeks and no later than 16 weeks |
| Stop | 36 weeks in ASPRE; continuing to birth is also acceptable practice |
| Calcium | 1.5 to 2 g elemental calcium daily from around 20 weeks if dietary intake is low |
- ASPRE: 1,776 women at high risk by the competing-risks model, aspirin 150 mg nightly from 11 to 14 weeks until 36 weeks. Preterm preeclampsia fell from 4.3% to 1.6% (odds ratio 0.38, 95% CI 0.20 to 0.74; P = 0.004), with no significant excess of neonatal adverse events.[1]
- Roberge dose-response meta-analysis: 45 trials, 20,909 women, doses 50 to 150 mg. Started at or before 16 weeks, aspirin reduced preeclampsia (RR 0.57), severe preeclampsia (RR 0.47) and fetal growth restriction (RR 0.56), each with a significant dose-response. Started after 16 weeks the effect on preeclampsia shrank to RR 0.81 with no dose-response, and there was no effect on severe preeclampsia or growth restriction.[2]
- Calcium: the Cochrane review found high-dose calcium (1 g per day or more) may reduce preeclampsia and preterm birth, particularly with low-calcium diets, and reduces the composite of maternal death or serious morbidity, on low-quality evidence.[7]
- State what you will not offer: bed rest, salt restriction, vitamins C and E, fish oil and garlic do not prevent preeclampsia.[4][8]
(c) First-trimester combined screening (4 marks)
One mark for the four inputs, one for the gestational window, one for performance, one for the comparison with the checklist. [6][5]
- Window: 11 to 13+6 weeks, usually alongside the aneuploidy screen.[6]
- Four inputs: maternal factors (age, weight, height, ethnicity, parity, obstetric and medical history, conception method); mean arterial pressure; uterine artery pulsatility index; and serum placental growth factor (PAPP-A as an alternative where placental growth factor is unavailable).[6]
- Performance: O'Gorman reported detection of 75% of preterm preeclampsia and 47% of term preeclampsia at a 10% false-positive rate, with PAPP-A adding little once placental growth factor was included.[6]
- Head-to-head: in SPREE (16,747 pregnancies) at a screen-positive rate of 10.3%, the NICE checklist detected 40.8% of preterm preeclampsia; maternal factors plus mean arterial pressure plus placental growth factor reached 69.0%; adding uterine artery pulsatility index reached 82.4%.[5]
- The implementation caveat that earns the last mark: SPREE found compliance with the NICE recommendation to give first-trimester aspirin to high-risk women was only 23%. A better screen is worthless without the prescription.[5]
(d) Counselling about residual risk (2 marks)
One mark for honesty about relative rather than absolute protection, one for the surveillance and safety-net message. [1][9]
- "Aspirin substantially reduces the chance of preeclampsia coming early, but it does not guarantee it will not happen. In the ASPRE trial the risk of preterm preeclampsia fell from about 4 in 100 to about 2 in 100 in women at high risk."[1]
- "It has much less effect on preeclampsia at term, so we will still watch you closely: blood pressure and urine at every visit, growth scans, and a written list of symptoms that should bring you straight in."[1][8]
- "If it does happen again, that will not be because you did anything wrong."[9]
References9ShowHide
- [1]Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia N Engl J Med, 2017.PMID 28657417
- [2]Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis Am J Obstet Gynecol, 2017.PMID 27640943
- [3]Davidson KW, Barry MJ, Mangione CM, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement JAMA, 2021.PMID 34581729
- [4]Henderson JT, Vesco KK, Senger CA, Thomas RG, Redmond N Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force JAMA, 2021.PMID 34581730
- [5]Tan MY, Wright D, Syngelaki A, et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE Ultrasound Obstet Gynecol, 2018.PMID 29536574
- [6]O'Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation Am J Obstet Gynecol, 2016.PMID 26297382
- [7]Hofmeyr GJ, Lawrie TA, Atallah ÁN, Torloni MR Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems Cochrane Database Syst Rev, 2018.PMID 30277579
- [8]Shanmugalingam R, Barrett HL, Beech A, et al. A summary of the 2023 Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) hypertension in pregnancy guideline Med J Aust, 2024.PMID 38763516
- [9]Brouwers L, van der Meiden-van Roest AJ, Savelkoul C, et al. Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis BJOG, 2018.PMID 29978553